UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017133
Receipt number R000019810
Scientific Title Assessment of Safety of a Supplement Containing Mushroom Chitosan in Case of Excess Ingestion
Date of disclosure of the study information 2015/04/14
Last modified on 2015/04/14 09:10:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Assessment of Safety of a Supplement Containing Mushroom Chitosan in Case of Excess Ingestion

Acronym

Safety of a Supplement Containing Mushroom Chitosan

Scientific Title

Assessment of Safety of a Supplement Containing Mushroom Chitosan in Case of Excess Ingestion

Scientific Title:Acronym

Safety of a Supplement Containing Mushroom Chitosan

Region

Japan


Condition

Condition

Safty varification of a supplement containing mushroom chitosan

Classification by specialty

Not applicable

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to evaluate safty of a supplement containing mushroom chitosan in case of excess ingestion.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Body structure
Blood pressure
Pulsation
Blood biochemistry test
Urine analysis
Doctor's questions

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Oral ingestion of the test product (4 weeks)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

59 years-old >

Gender

Male and Female

Key inclusion criteria

[1]Japanese males and females aged 20-59 years
[2]Individuals whose BMI is less than 25 kg/m^2 (12 subjects)
[3]Individuals whose BMI is over 25 kg/m^2 (12subjects)

Key exclusion criteria

[1]Individuals using or will use medical products
[2]Individuals who had a habit to ingest health-promoting foods
[3]Individuals who are or are posslibly, or are lactating
[4]Individuals who excessively take alcohol
[5]Individuals who have symptoms of allergy to the test product
[6]Individuals who participate in other clinical studies
[7]Individuals who have a history of serious hepatopathy, kidney damage, heart disease and hematological disease
[8]Individuals with serious anemia
[9]Individuals who had been administrated contrast material (ex. barium) in the past 2 months or will be administrated during the test period

Target sample size

24


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Akimasa Matsuyama

Organization

Shirogane EXE Clinic

Division name

Internal Medicine

Zip code


Address

2F Charming Square Shirogane, 6-16-6 Shirogane Minato-ku Tokyo 108-0072, JAPAN

TEL

03-5939-0701

Email

info@tes-h.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name TES Holdings Co., Ltd.

Organization

TES Holdings Co., Ltd.

Division name

Department of Clinical Trial

Zip code


Address

6F University of Tokyo Entrepreneur Plaza, 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033, JAPAN

TEL

03-6801-8480

Homepage URL


Email

info@tes-h.co.jp


Sponsor or person

Institute

TES Holdings Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

RICOM Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 04 Month 14 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2008 Year 06 Month 01 Day

Date of IRB


Anticipated trial start date

2008 Year 06 Month 14 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 04 Month 14 Day

Last modified on

2015 Year 04 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019810


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name